IR@PKUHSC  > 北京大学第三临床医学院  > 药剂科
学科主题临床医学
The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients
Li, Y.3,4; Tang, H. -L.3; Hu, Y. -F.3; Xie, H. -G.1,2
关键词Bleeding Clopidogrel cyp2c19*17 Polymorphism Major Adverse Cardiovascular Events Meta-analysis Platelet
刊名JOURNAL OF THROMBOSIS AND HAEMOSTASIS
2012-02-01
DOI10.1111/j.1538-7836.2011.04570.x
10期:2页:199-206
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Hematology ; Peripheral Vascular Disease
资助者National Natural Science Foundation of China ; State Key Basic Research and Development Plan ; National Natural Science Foundation of China ; State Key Basic Research and Development Plan
研究领域[WOS]Hematology ; Cardiovascular System & Cardiology
关键词[WOS]ACUTE CORONARY SYNDROMES ; ADVERSE CLINICAL-OUTCOMES ; CYP2C19 GENOTYPE ; CARDIOVASCULAR EVENTS ; PLATELET-AGGREGATION ; GENETIC-VARIANTS ; STENT THROMBOSIS ; IN-VITRO ; METAANALYSIS ; POLYMORPHISMS
英文摘要

. Background: A large number of clinical studies have documented that a loss-of-function variant CYP2C19*2 affects clinical profiles of clopidogrel (efficacy and safety). However, data on the impact of a gain-of-function variant CYP2C19*17 on the response to that drug seem to be less consistent. Objectives: To systematically summarize all available clinical data assessing the role of the CYP2C19*17 variant in patients taking clopidogrel. Methods: A literature search was conducted and a meta-analysis was performed for 11 eligible studies. The endpoints included the major adverse cardiovascular events (MACE, representing non-fatal myocardial infarction, stroke, revascularization, or death), bleeding events, mortality, stent thrombosis and high platelet reactivity (HPR). Results: Data from six clinical studies demonstrated that carriers of the CYP2C19*17 variant had a marked protection against recurrent cardiovascular events in patients with coronary artery disease compared with non-carriers, as measured by a 16% decrease in the incidence of MACE (10.0% vs. 11.9%; OR, 0.82; 95% CI, 0.720.94; P = 0.005). On the other hand, carriers had an increased risk of developing bleeding as expected (8.0% vs. 6.5%; OR, 1.25; 95% CI, 1.071.47; P = 0.006; four studies). Moreover, the presence of the CYP2C19*17 variant might lead to increased response to clopidogrel, as shown by a marked lower prevalence of HPR in carriers than in non-carriers (37.9% vs. 50.8%; OR, 0.60; 95% CI, 0.450.79; P = 0.0003; three studies). Conclusions: Carriers of the CYP2C19*17 variant have greater therapeutic responsiveness to clopidogrel than non-carriers, but they have an increased risk of developing bleeding as well.

语种英语
所属项目编号81072705 ; 2011CB915504
资助者National Natural Science Foundation of China ; State Key Basic Research and Development Plan ; National Natural Science Foundation of China ; State Key Basic Research and Development Plan
WOS记录号WOS:000299779500004
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/53577
专题北京大学第三临床医学院_药剂科
作者单位1.Nanjing Med Univ, Cent Lab, Nanjing 210006, Jiangsu, Peoples R China
2.Nanjing Med Univ, Nanjing Hosp 1, Dept Clin Pharmacol, Nanjing 210006, Jiangsu, Peoples R China
3.Peking Univ, Dept Pharm, Therapeut Drug Monitoring & Clin Toxicol Ctr, Hosp 3, Beijing 100191, Peoples R China
4.Peking Univ, Dept Pharm Adm & Clin Pharm, Sch Pharmaceut Sci, Hlth Sci Ctr, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Li, Y.,Tang, H. -L.,Hu, Y. -F.,et al. The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients[J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS,2012,10(2):199-206.
APA Li, Y.,Tang, H. -L.,Hu, Y. -F.,&Xie, H. -G..(2012).The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients.JOURNAL OF THROMBOSIS AND HAEMOSTASIS,10(2),199-206.
MLA Li, Y.,et al."The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients".JOURNAL OF THROMBOSIS AND HAEMOSTASIS 10.2(2012):199-206.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Li, Y.]的文章
[Tang, H. -L.]的文章
[Hu, Y. -F.]的文章
百度学术
百度学术中相似的文章
[Li, Y.]的文章
[Tang, H. -L.]的文章
[Hu, Y. -F.]的文章
必应学术
必应学术中相似的文章
[Li, Y.]的文章
[Tang, H. -L.]的文章
[Hu, Y. -F.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。